Clinical Trials
40 trialsStudy of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Washington University School of Medicine
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Dana-Farber Cancer Institute
SINE
University of Chicago
A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
National University Hospital, Singapore
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Chinese PLA General Hospital
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
University Health Network, Toronto
KPT-IST-391
Oncotherapeutics
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Vanderbilt-Ingram Cancer Center
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
St. Jude Children's Research Hospital
SeliSarc
Grupo Espanol de Investigacion en Sarcomas
A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
Karyopharm Therapeutics Inc
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Oncotherapeutics
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
KPT-330
Ohio State University Comprehensive Cancer Center
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Karyopharm Therapeutics Inc
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Karyopharm Therapeutics Inc
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
H. Lee Moffitt Cancer Center and Research Institute
KPT-330+RICE
Weill Medical College of Cornell University
SENTINEL
GSO Global Clinical Research BV
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
University Health Network, Toronto
SELINDA
The Lymphoma Academic Research Organisation
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
University of Chicago
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
National Cancer Centre, Singapore
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
Columbia University
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Memorial Sloan Kettering Cancer Center
Phase I Study of KPT330 in Asian Patients
National University Hospital, Singapore
FLAGINEXOR
PETHEMA Foundation
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
University of Chicago
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
H. Lee Moffitt Cancer Center and Research Institute
Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
Sheba Medical Center